HORSHAM, PA — STRATA Skin Sciences, Inc. (NASDAQ: SSKN) has announced the publication of a clinical study highlighting the effectiveness of its TheraClear®X Acne Therapy System. The study, titled “Advancing precision acne therapy using a photopneumatic device,” appears in the July 11, 2024 issue of the Journal of Cosmetic and Laser Therapy.
The TheraClear®X system is shown to reduce acne lesions and redness while improving skin texture and pore size after one to three treatments. The treatment has few side effects, making it a beneficial option both as a standalone therapy and as an adjunct to other treatments. The device allows for customized treatment by adjusting pulse structure, duration, vacuum pressure, and energy intensity to suit different skin types and acne conditions.
The study evaluated seven female patients with various types of acne over six treatments spaced one to two weeks apart. Each treatment lasted 15-20 minutes using customized energy settings. Results were promising:
- All patients saw a visible reduction in acne lesions, achieving over 50% clearance after three treatments.
- Improvements were noted in skin texture, redness, pore size, oiliness, and acne-induced hyperpigmentation.
- Side effects were mild and included temporary redness, bruising, and pigmentation changes lasting 48-72 hours.
- Patients reported that the treatment was comfortable.
Dr. Gilly Munavalli, the study’s lead investigator, expressed satisfaction with the results. “The study shows TheraClear®X as a monotherapy is well tolerated and delivers visible improvements in facial acne lesions and skin texture,” he said. The ability to tailor vacuum and energy settings based on individual acne severity offers a personalized approach, making it an appealing alternative for those resistant to traditional treatments.
The TheraClearX system, FDA-cleared for treating mild-to-moderate acne, combines vacuum and pulsed broadband light. This method pulls dermal structures to the skin’s surface and removes follicular contents. The light activates porphyrins to destroy acne-causing bacteria and reduce sebum production. The treatment is noninvasive, requires no pre-medication or anesthesia, and has no downtime.
Dr. Dolev Rafaeli, STRATA’s President and CEO, highlighted the significance of the findings. “Acne affects tens of millions of people each year just in the U.S. alone, and can prove difficult to treat with only a topical or oral treatment. Photopneumatic therapy is emerging as a viable treatment modality, and it is gratifying to see proven results in a growing number of investigator-initiated studies.”
The study solidifies TheraClear®X’s position as a promising tool in dermatological therapy, offering hope to many who struggle with acne.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.